Application for Triple-Combination Therapy Submitted to the FDA

Vertex Pharmaceuticals Inc. announced today that it submitted a New Drug Application to the U.S. Food and Drug Administration for the approval of the first triple-combination therapy for cystic fibrosis.

| 1 min read

Today, Vertex announced that it has submitted a New Drug Application to the FDA for the approval of its triple-combination therapy -- elexacaftor (VX-445), tezacaftor, and ivacaftor.  Vertex confirmed it is seeking priority review, which, if granted by the FDA, would shorten the regulatory review to eight months from the time of submission versus the standard review time of one year. Topline results from the Phase 3 trial that was the basis of Vertex's application were announced earlier this year.

For additional information, please see the Vertex press release.

Share this article
Research | Drug Pipeline
Recent news
CF Foundation Invests Up to $3 Million in ViaNautis Bio to Explore a New Method to Deliver Genetic Therapies to People With CF
News | 2 min read
CF Foundation Formalizes Final Set of Recommendations From External Racial Justice Working Group
News | 4 min read
CF Foundation Awards Advance Improvements in CF Newborn Screening
News | 4 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.